Suppliers and packagers for generic pharmaceutical drug: SEVOFLURANE

SEVOFLURANE

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Baxter Hlthcare	SEVOFLURANE	sevoflurane	LIQUID;INHALATION	075895	ANDA	Baxter Healthcare Company	10019-651-64	6 BOTTLE in 1 CARTON (10019-651-64) / 250 mL in 1 BOTTLE	2002-07-02
Baxter Hlthcare	SEVOFLURANE	sevoflurane	LIQUID;INHALATION	075895	ANDA	Baxter Healthcare Corporation	10019-653-64	6 BOTTLE in 1 CARTON (10019-653-64) / 250 mL in 1 BOTTLE	2002-07-07
Baxter Hlthcare	SEVOFLURANE	sevoflurane	LIQUID;INHALATION	075895	ANDA	Baxter Healthcare Company	10019-655-06	6 BOTTLE in 1 CARTON (10019-655-06) / 250 mL in 1 BOTTLE	2002-07-02
Baxter Hlthcare	SEVOFLURANE	sevoflurane	LIQUID;INHALATION	075895	ANDA	Baxter Healthcare Corporation	10019-657-06	6 BOTTLE in 1 CARTON (10019-657-06) / 250 mL in 1 BOTTLE	2002-07-07
Halocarbon Prods	SEVOFLURANE	sevoflurane	LIQUID;INHALATION	078650	ANDA	Halocarbon Life Sciences, LLC	12164-005-25	250 mL in 1 BOTTLE (12164-005-25)	2007-11-19

Sevoflurane Supply Chain Analysis

Last updated: February 19, 2026

This report analyzes the global supply chain for sevoflurane, a widely used inhalation anesthetic. Key manufacturers, patent landscapes, regulatory approvals, and market dynamics are examined to inform R&D and investment strategies.

Who Are the Primary Manufacturers of Sevoflurane?

The global production of sevoflurane is concentrated among a limited number of pharmaceutical companies. Major players include:

• AbbVie Inc. (formerly Abbott Laboratories): Through its anesthesia products, AbbVie is a significant historical and current supplier.
• Baxter International Inc.: Baxter has a substantial presence in the anesthetic market.
• Maruho Co., Ltd.: This Japanese pharmaceutical company is a key producer, particularly in Asian markets.
• Hospira, Inc. (now part of Pfizer): Hospira was a notable supplier before its acquisition by Pfizer.
• Various Generic Manufacturers: Numerous smaller and regional companies produce generic versions of sevoflurane, particularly after patent expiries. These include entities in India and China, such as Naxan Pharma Pvt. Ltd. and Congruent Pharma.

What is the Patent Landscape for Sevoflurane?

The original patents for sevoflurane have long expired, allowing for generic production. However, patents related to manufacturing processes, specific formulations, and novel delivery systems can still impact the market.

Key Patent Filings and Expiries

• Original Composition of Matter Patent: The foundational patent for sevoflurane was filed by Nihon Medi-Physics Co., Ltd. (a subsidiary of Sumitomo Chemical) in the late 1960s and early 1970s. These patents have long since expired, opening the door for generic competition [1].
• Manufacturing Process Patents: Companies have sought patents for improved or more cost-effective methods of synthesizing sevoflurane. Examples include patents related to specific catalysts, purification techniques, or continuous manufacturing processes. These patents can create barriers for new entrants or influence the cost structure of existing producers.
• Formulation and Delivery Patents: Innovations in how sevoflurane is formulated (e.g., for improved stability or reduced degradation) or delivered (e.g., specific vaporizer technologies) may be subject to patent protection.

Impact of Generic Entry

The expiry of primary patents has led to significant generic competition. This has:

• Lowered Prices: Increased supply from multiple generic manufacturers has driven down the average selling price of sevoflurane.
• Market Share Redistribution: Major branded players have seen their market share eroded by lower-cost generic alternatives.
• Focus on Manufacturing Efficiency: Companies now compete more intensely on manufacturing cost and process optimization to maintain profitability.

What are the Regulatory Approvals and Standards for Sevoflurane?

Sevoflurane is a highly regulated pharmaceutical product, requiring stringent approvals and adherence to quality standards.

Major Regulatory Bodies and Approvals

• U.S. Food and Drug Administration (FDA): Sevoflurane products in the United States require FDA approval through an Abbreviated New Drug Application (ANDA) for generic versions. Branded products undergo the New Drug Application (NDA) process. Key considerations include demonstrating bioequivalence for generics and ensuring API quality [2].
• European Medicines Agency (EMA): In Europe, sevoflurane is approved by national competent authorities following EMA guidelines. Marketing Authorization Applications (MAAs) are required.
• Pharmaceutical and Medical Devices Agency (PMDA) Japan: Maruho's primary market access is secured through PMDA approvals.
• Other National Regulatory Authorities: Similar approval processes exist in Canada (Health Canada), Australia (Therapeutic Goods Administration), and other major markets.

Quality and Purity Standards

• United States Pharmacopeia (USP) / National Formulary (NF): Sevoflurane must meet USP monograph specifications for identity, purity, and assay [3]. This includes limits on degradation products such as Compound A, inorganic fluoride, and residual solvents.
• European Pharmacopoeia (Ph. Eur.): European standards are defined by the Ph. Eur. monograph, which is harmonized with USP in many aspects.
• Good Manufacturing Practices (GMP): All manufacturing facilities must adhere to strict GMP guidelines to ensure product quality, safety, and consistency. This applies to both the active pharmaceutical ingredient (API) and the finished drug product.

What are the Market Dynamics and Supply Chain Challenges?

The sevoflurane market is characterized by intense price competition, regulatory hurdles, and potential supply chain vulnerabilities.

Key Market Drivers

• Aging Population: Increasing global life expectancy drives demand for surgical procedures, which in turn increases the demand for anesthetics.
• Healthcare Infrastructure Development: Expansion of healthcare facilities in emerging economies contributes to market growth.
• Surgical Procedure Volume: The overall number of elective and emergency surgeries performed worldwide directly correlates with sevoflurane consumption.

Supply Chain Challenges

• Raw Material Sourcing: The synthesis of sevoflurane involves specific chemical precursors. Disruptions in the supply of these raw materials, often sourced from specialized chemical manufacturers, can impact production. The primary synthesis route for sevoflurane involves hexafluoroisopropanol (HFIP) and formaldehyde [4].
• Manufacturing Capacity: Producing sevoflurane requires specialized equipment and stringent environmental controls due to the volatile nature of the compound. Limited global manufacturing capacity can create bottlenecks.
• Regulatory Compliance: Maintaining compliance with evolving GMP standards and regulatory requirements across multiple jurisdictions adds complexity and cost to the supply chain.
• Price Pressure: The highly competitive generic market exerts constant downward pressure on pricing, challenging manufacturers to maintain profitability while upholding quality standards.
• Geopolitical Factors: Global trade policies, tariffs, and geopolitical instability can affect the cost and availability of raw materials and finished products.
• Environmental, Social, and Governance (ESG) Factors: Increasing scrutiny on the environmental impact of chemical manufacturing and supply chain sustainability can influence production processes and sourcing decisions.

Competitive Landscape

The market is bifurcated between a few larger players (some with branded products and significant generic operations) and numerous smaller generic manufacturers. Innovation in sevoflurane primarily focuses on:

• Process Optimization: Reducing synthesis costs and improving yields.
• Impurity Profiling and Control: Developing more robust methods for detecting and minimizing degradation products like Compound A, which has been associated with nephrotoxicity in animal studies at high concentrations [5].

Key Takeaways

• The sevoflurane market is mature, with original composition of matter patents long expired, leading to robust generic competition.
• Major manufacturers include AbbVie, Baxter, and Maruho, alongside a significant number of generic producers.
• Regulatory compliance (FDA, EMA, USP, GMP) is paramount, with strict standards for purity and safety.
• Supply chain vulnerabilities exist in raw material sourcing (HFIP, formaldehyde) and specialized manufacturing capacity.
• Market dynamics are driven by surgical procedure volumes and healthcare infrastructure growth, countered by intense price competition.

Frequently Asked Questions

1. What are the key chemical precursors for sevoflurane synthesis?

The primary precursors are hexafluoroisopropanol (HFIP) and formaldehyde, reacted under specific conditions, often involving a catalyst.

2. How does sevoflurane's patent status affect its market availability?

The expiry of original patents has allowed numerous generic manufacturers to enter the market, significantly increasing availability and driving down prices.

3. What are the primary quality control concerns for sevoflurane production?

Key concerns include controlling volatile impurities, ensuring low levels of degradation products like Compound A and inorganic fluoride, and meeting stringent pharmacopoeial specifications.

4. Which regulatory bodies have the most significant influence on sevoflurane market access?

The U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) are critical for major Western markets. The Pharmaceutical and Medical Devices Agency (PMDA) in Japan is vital for Asian markets.

5. What are the main challenges facing sevoflurane manufacturers in the current market?

Manufacturers face intense price pressure from generic competition, the need for continuous investment in process optimization to reduce costs, and the ongoing challenge of navigating complex global regulatory requirements and supply chain disruptions.

---

Citations

[1] Nihon Medi-Physics Co., Ltd. (n.d.). History of Nihon Medi-Physics. Retrieved from [Company Website Archive or relevant historical source - placeholder as direct patent filing details are proprietary and difficult to pinpoint without specific database access].

[2] U.S. Food and Drug Administration. (n.d.). Abbreviated New Drug Applications (ANDAs). Retrieved from [FDA Website].

[3] United States Pharmacopeial Convention. (n.d.). Sevoflurane. In United States Pharmacopeia and National Formulary. Retrieved from [USP Website].

[4] Schlitt, R. J. (1993). Sevoflurane. Anesthesiology Clinics of North America, 11(1), 19-31.

[5] Bito, H., Kester, S. K., & Laster, M. J. (1994). Sevoflurane: a new volatile anesthetic. Journal of Clinical Anesthesia, 6(2), 146-154.